Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2021-04, Vol.113 (4), p.443-452
Hauptverfasser: Magbanua, Mark Jesus M, Hendrix, Laura H, Hyslop, Terry, Barry, William T, Winer, Eric P, Hudis, Clifford, Toppmeyer, Deborah, Carey, Lisa Anne, Partridge, Ann H, Pierga, Jean-Yves, Fehm, Tanja, Vidal-Martínez, José, Mavroudis, Dimitrios, Garcia-Saenz, Jose A, Stebbing, Justin, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, Antelo, María Luisa, Mattos-Arruda, Leticia De, Generali, Daniele, Caldas, Carlos, Munzone, Elisabetta, Dirix, Luc, Delson, Amy L, Burstein, Harold J, Qadir, Misbah, Ma, Cynthia, Scott, Janet H, Bidard, François-Clément, Park, John W, Rugo, Hope S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 452
container_issue 4
container_start_page 443
container_title JNCI : Journal of the National Cancer Institute
container_volume 113
creator Magbanua, Mark Jesus M
Hendrix, Laura H
Hyslop, Terry
Barry, William T
Winer, Eric P
Hudis, Clifford
Toppmeyer, Deborah
Carey, Lisa Anne
Partridge, Ann H
Pierga, Jean-Yves
Fehm, Tanja
Vidal-Martínez, José
Mavroudis, Dimitrios
Garcia-Saenz, Jose A
Stebbing, Justin
Gazzaniga, Paola
Manso, Luis
Zamarchi, Rita
Antelo, María Luisa
Mattos-Arruda, Leticia De
Generali, Daniele
Caldas, Carlos
Munzone, Elisabetta
Dirix, Luc
Delson, Amy L
Burstein, Harold J
Qadir, Misbah
Ma, Cynthia
Scott, Janet H
Bidard, François-Clément
Park, John W
Rugo, Hope S
description Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.
doi_str_mv 10.1093/jnci/djaa113
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8023821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jnci/djaa113</oup_id><sourcerecordid>2431807169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhoMo7uzqzbMEPOjBdisf3UkuwtrsqjAi6HoO6XR6J0N3MibdC_PvzTDjoh6sSxXUUy9V9SL0gsA7AopdboP1l_3WGELYI7QivIGKEqgfoxUAFZWUgp-h85y3UEJR_hSdMSoEUC5WaPPdJW9GfBXMuM8-4zjg1ie7jGb24Q7fLlNMuHXjmLEP-IubTZ5Ly-IPyZUStyZYl_A3Z52_P0zc-JTnau2Dw-3GTXHeuGR2-2foyWDG7J6f8gX6cXN9236q1l8_fm6v1pXlnM9VJxUfmOrMQGrBBk44ZaY2bIBOdqInDmjNpeHAQQFVDW1I39S9ooJwBRbYBXp_1N0t3eR668KczKh3yU8m7XU0Xv_dCX6j7-K9lkCZpKQIvDkJpPhzcXnWk8-2PMAEF5esKWdEgiCNKuirf9BtXFL5ZKFqJWQNhPFCvT1SNsWckxseliGgDxbqg4X6ZGHBX_55wAP827MCvD4Ccdn9X-oX28Klrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2597850134</pqid></control><display><type>article</type><title>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Magbanua, Mark Jesus M ; Hendrix, Laura H ; Hyslop, Terry ; Barry, William T ; Winer, Eric P ; Hudis, Clifford ; Toppmeyer, Deborah ; Carey, Lisa Anne ; Partridge, Ann H ; Pierga, Jean-Yves ; Fehm, Tanja ; Vidal-Martínez, José ; Mavroudis, Dimitrios ; Garcia-Saenz, Jose A ; Stebbing, Justin ; Gazzaniga, Paola ; Manso, Luis ; Zamarchi, Rita ; Antelo, María Luisa ; Mattos-Arruda, Leticia De ; Generali, Daniele ; Caldas, Carlos ; Munzone, Elisabetta ; Dirix, Luc ; Delson, Amy L ; Burstein, Harold J ; Qadir, Misbah ; Ma, Cynthia ; Scott, Janet H ; Bidard, François-Clément ; Park, John W ; Rugo, Hope S</creator><creatorcontrib>Magbanua, Mark Jesus M ; Hendrix, Laura H ; Hyslop, Terry ; Barry, William T ; Winer, Eric P ; Hudis, Clifford ; Toppmeyer, Deborah ; Carey, Lisa Anne ; Partridge, Ann H ; Pierga, Jean-Yves ; Fehm, Tanja ; Vidal-Martínez, José ; Mavroudis, Dimitrios ; Garcia-Saenz, Jose A ; Stebbing, Justin ; Gazzaniga, Paola ; Manso, Luis ; Zamarchi, Rita ; Antelo, María Luisa ; Mattos-Arruda, Leticia De ; Generali, Daniele ; Caldas, Carlos ; Munzone, Elisabetta ; Dirix, Luc ; Delson, Amy L ; Burstein, Harold J ; Qadir, Misbah ; Ma, Cynthia ; Scott, Janet H ; Bidard, François-Clément ; Park, John W ; Rugo, Hope S</creatorcontrib><description>Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P &lt; .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djaa113</identifier><identifier>PMID: 32770247</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Chemotherapy ; Clinical trials ; Criteria ; Female ; Humans ; Metastases ; Metastasis ; Neoplastic Cells, Circulating - pathology ; Patients ; Prognosis ; Progression-Free Survival ; Proportional Hazards Models ; Reproducibility of Results ; Retrospective Studies ; Statistical analysis ; Statistical methods ; Survival ; Treatment Outcome ; Tumor cells ; Tumors</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2021-04, Vol.113 (4), p.443-452</ispartof><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</citedby><cites>FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</cites><orcidid>0000-0002-4722-4824 ; 0000-0001-7144-8791 ; 0000-0003-3371-3878 ; 0000-0003-3547-1489 ; 0000-0001-5932-8949 ; 0000-0003-2113-3593 ; 0000-0001-6710-4814 ; 0000-0001-6435-2257 ; 0000-0001-6880-0301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32770247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magbanua, Mark Jesus M</creatorcontrib><creatorcontrib>Hendrix, Laura H</creatorcontrib><creatorcontrib>Hyslop, Terry</creatorcontrib><creatorcontrib>Barry, William T</creatorcontrib><creatorcontrib>Winer, Eric P</creatorcontrib><creatorcontrib>Hudis, Clifford</creatorcontrib><creatorcontrib>Toppmeyer, Deborah</creatorcontrib><creatorcontrib>Carey, Lisa Anne</creatorcontrib><creatorcontrib>Partridge, Ann H</creatorcontrib><creatorcontrib>Pierga, Jean-Yves</creatorcontrib><creatorcontrib>Fehm, Tanja</creatorcontrib><creatorcontrib>Vidal-Martínez, José</creatorcontrib><creatorcontrib>Mavroudis, Dimitrios</creatorcontrib><creatorcontrib>Garcia-Saenz, Jose A</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><creatorcontrib>Gazzaniga, Paola</creatorcontrib><creatorcontrib>Manso, Luis</creatorcontrib><creatorcontrib>Zamarchi, Rita</creatorcontrib><creatorcontrib>Antelo, María Luisa</creatorcontrib><creatorcontrib>Mattos-Arruda, Leticia De</creatorcontrib><creatorcontrib>Generali, Daniele</creatorcontrib><creatorcontrib>Caldas, Carlos</creatorcontrib><creatorcontrib>Munzone, Elisabetta</creatorcontrib><creatorcontrib>Dirix, Luc</creatorcontrib><creatorcontrib>Delson, Amy L</creatorcontrib><creatorcontrib>Burstein, Harold J</creatorcontrib><creatorcontrib>Qadir, Misbah</creatorcontrib><creatorcontrib>Ma, Cynthia</creatorcontrib><creatorcontrib>Scott, Janet H</creatorcontrib><creatorcontrib>Bidard, François-Clément</creatorcontrib><creatorcontrib>Park, John W</creatorcontrib><creatorcontrib>Rugo, Hope S</creatorcontrib><title>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P &lt; .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Criteria</subject><subject>Female</subject><subject>Humans</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Proportional Hazards Models</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Statistical methods</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhoMo7uzqzbMEPOjBdisf3UkuwtrsqjAi6HoO6XR6J0N3MibdC_PvzTDjoh6sSxXUUy9V9SL0gsA7AopdboP1l_3WGELYI7QivIGKEqgfoxUAFZWUgp-h85y3UEJR_hSdMSoEUC5WaPPdJW9GfBXMuM8-4zjg1ie7jGb24Q7fLlNMuHXjmLEP-IubTZ5Ly-IPyZUStyZYl_A3Z52_P0zc-JTnau2Dw-3GTXHeuGR2-2foyWDG7J6f8gX6cXN9236q1l8_fm6v1pXlnM9VJxUfmOrMQGrBBk44ZaY2bIBOdqInDmjNpeHAQQFVDW1I39S9ooJwBRbYBXp_1N0t3eR668KczKh3yU8m7XU0Xv_dCX6j7-K9lkCZpKQIvDkJpPhzcXnWk8-2PMAEF5esKWdEgiCNKuirf9BtXFL5ZKFqJWQNhPFCvT1SNsWckxseliGgDxbqg4X6ZGHBX_55wAP827MCvD4Ccdn9X-oX28Klrw</recordid><startdate>20210406</startdate><enddate>20210406</enddate><creator>Magbanua, Mark Jesus M</creator><creator>Hendrix, Laura H</creator><creator>Hyslop, Terry</creator><creator>Barry, William T</creator><creator>Winer, Eric P</creator><creator>Hudis, Clifford</creator><creator>Toppmeyer, Deborah</creator><creator>Carey, Lisa Anne</creator><creator>Partridge, Ann H</creator><creator>Pierga, Jean-Yves</creator><creator>Fehm, Tanja</creator><creator>Vidal-Martínez, José</creator><creator>Mavroudis, Dimitrios</creator><creator>Garcia-Saenz, Jose A</creator><creator>Stebbing, Justin</creator><creator>Gazzaniga, Paola</creator><creator>Manso, Luis</creator><creator>Zamarchi, Rita</creator><creator>Antelo, María Luisa</creator><creator>Mattos-Arruda, Leticia De</creator><creator>Generali, Daniele</creator><creator>Caldas, Carlos</creator><creator>Munzone, Elisabetta</creator><creator>Dirix, Luc</creator><creator>Delson, Amy L</creator><creator>Burstein, Harold J</creator><creator>Qadir, Misbah</creator><creator>Ma, Cynthia</creator><creator>Scott, Janet H</creator><creator>Bidard, François-Clément</creator><creator>Park, John W</creator><creator>Rugo, Hope S</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4722-4824</orcidid><orcidid>https://orcid.org/0000-0001-7144-8791</orcidid><orcidid>https://orcid.org/0000-0003-3371-3878</orcidid><orcidid>https://orcid.org/0000-0003-3547-1489</orcidid><orcidid>https://orcid.org/0000-0001-5932-8949</orcidid><orcidid>https://orcid.org/0000-0003-2113-3593</orcidid><orcidid>https://orcid.org/0000-0001-6710-4814</orcidid><orcidid>https://orcid.org/0000-0001-6435-2257</orcidid><orcidid>https://orcid.org/0000-0001-6880-0301</orcidid></search><sort><creationdate>20210406</creationdate><title>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</title><author>Magbanua, Mark Jesus M ; Hendrix, Laura H ; Hyslop, Terry ; Barry, William T ; Winer, Eric P ; Hudis, Clifford ; Toppmeyer, Deborah ; Carey, Lisa Anne ; Partridge, Ann H ; Pierga, Jean-Yves ; Fehm, Tanja ; Vidal-Martínez, José ; Mavroudis, Dimitrios ; Garcia-Saenz, Jose A ; Stebbing, Justin ; Gazzaniga, Paola ; Manso, Luis ; Zamarchi, Rita ; Antelo, María Luisa ; Mattos-Arruda, Leticia De ; Generali, Daniele ; Caldas, Carlos ; Munzone, Elisabetta ; Dirix, Luc ; Delson, Amy L ; Burstein, Harold J ; Qadir, Misbah ; Ma, Cynthia ; Scott, Janet H ; Bidard, François-Clément ; Park, John W ; Rugo, Hope S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-b894f39baf1573f41423a5a3f0b8b7d1e02548a404090296261d65d9271490c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Criteria</topic><topic>Female</topic><topic>Humans</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Proportional Hazards Models</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Statistical methods</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magbanua, Mark Jesus M</creatorcontrib><creatorcontrib>Hendrix, Laura H</creatorcontrib><creatorcontrib>Hyslop, Terry</creatorcontrib><creatorcontrib>Barry, William T</creatorcontrib><creatorcontrib>Winer, Eric P</creatorcontrib><creatorcontrib>Hudis, Clifford</creatorcontrib><creatorcontrib>Toppmeyer, Deborah</creatorcontrib><creatorcontrib>Carey, Lisa Anne</creatorcontrib><creatorcontrib>Partridge, Ann H</creatorcontrib><creatorcontrib>Pierga, Jean-Yves</creatorcontrib><creatorcontrib>Fehm, Tanja</creatorcontrib><creatorcontrib>Vidal-Martínez, José</creatorcontrib><creatorcontrib>Mavroudis, Dimitrios</creatorcontrib><creatorcontrib>Garcia-Saenz, Jose A</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><creatorcontrib>Gazzaniga, Paola</creatorcontrib><creatorcontrib>Manso, Luis</creatorcontrib><creatorcontrib>Zamarchi, Rita</creatorcontrib><creatorcontrib>Antelo, María Luisa</creatorcontrib><creatorcontrib>Mattos-Arruda, Leticia De</creatorcontrib><creatorcontrib>Generali, Daniele</creatorcontrib><creatorcontrib>Caldas, Carlos</creatorcontrib><creatorcontrib>Munzone, Elisabetta</creatorcontrib><creatorcontrib>Dirix, Luc</creatorcontrib><creatorcontrib>Delson, Amy L</creatorcontrib><creatorcontrib>Burstein, Harold J</creatorcontrib><creatorcontrib>Qadir, Misbah</creatorcontrib><creatorcontrib>Ma, Cynthia</creatorcontrib><creatorcontrib>Scott, Janet H</creatorcontrib><creatorcontrib>Bidard, François-Clément</creatorcontrib><creatorcontrib>Park, John W</creatorcontrib><creatorcontrib>Rugo, Hope S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magbanua, Mark Jesus M</au><au>Hendrix, Laura H</au><au>Hyslop, Terry</au><au>Barry, William T</au><au>Winer, Eric P</au><au>Hudis, Clifford</au><au>Toppmeyer, Deborah</au><au>Carey, Lisa Anne</au><au>Partridge, Ann H</au><au>Pierga, Jean-Yves</au><au>Fehm, Tanja</au><au>Vidal-Martínez, José</au><au>Mavroudis, Dimitrios</au><au>Garcia-Saenz, Jose A</au><au>Stebbing, Justin</au><au>Gazzaniga, Paola</au><au>Manso, Luis</au><au>Zamarchi, Rita</au><au>Antelo, María Luisa</au><au>Mattos-Arruda, Leticia De</au><au>Generali, Daniele</au><au>Caldas, Carlos</au><au>Munzone, Elisabetta</au><au>Dirix, Luc</au><au>Delson, Amy L</au><au>Burstein, Harold J</au><au>Qadir, Misbah</au><au>Ma, Cynthia</au><au>Scott, Janet H</au><au>Bidard, François-Clément</au><au>Park, John W</au><au>Rugo, Hope S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>2021-04-06</date><risdate>2021</risdate><volume>113</volume><issue>4</issue><spage>443</spage><epage>452</epage><pages>443-452</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><abstract>Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P &lt; .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>32770247</pmid><doi>10.1093/jnci/djaa113</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4722-4824</orcidid><orcidid>https://orcid.org/0000-0001-7144-8791</orcidid><orcidid>https://orcid.org/0000-0003-3371-3878</orcidid><orcidid>https://orcid.org/0000-0003-3547-1489</orcidid><orcidid>https://orcid.org/0000-0001-5932-8949</orcidid><orcidid>https://orcid.org/0000-0003-2113-3593</orcidid><orcidid>https://orcid.org/0000-0001-6710-4814</orcidid><orcidid>https://orcid.org/0000-0001-6435-2257</orcidid><orcidid>https://orcid.org/0000-0001-6880-0301</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8874
ispartof JNCI : Journal of the National Cancer Institute, 2021-04, Vol.113 (4), p.443-452
issn 0027-8874
1460-2105
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8023821
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Chemotherapy
Clinical trials
Criteria
Female
Humans
Metastases
Metastasis
Neoplastic Cells, Circulating - pathology
Patients
Prognosis
Progression-Free Survival
Proportional Hazards Models
Reproducibility of Results
Retrospective Studies
Statistical analysis
Statistical methods
Survival
Treatment Outcome
Tumor cells
Tumors
title Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A35%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serial%20Analysis%20of%20Circulating%20Tumor%20Cells%20in%20Metastatic%20Breast%20Cancer%20Receiving%20First-Line%20Chemotherapy&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Magbanua,%20Mark%20Jesus%20M&rft.date=2021-04-06&rft.volume=113&rft.issue=4&rft.spage=443&rft.epage=452&rft.pages=443-452&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/djaa113&rft_dat=%3Cproquest_pubme%3E2431807169%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2597850134&rft_id=info:pmid/32770247&rft_oup_id=10.1093/jnci/djaa113&rfr_iscdi=true